Compounds for the treatment of hepatitis C

US8741884B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Tao Wang · Farmington, US
• Zhiwei Yin · Glastonbury, US
• Zhongxing Zhang · Wallingford, US
• Annapurna Pendri · South Glastonbury, US
• Guo Li · Chengdu, CN
• Samuel Gerritz · Guilford, US
• Weixu Zhai · Middletown, US
• Paul Michael Scola · Glastonbury, US
• Li-Qiang Sun · Foster City, US
• Eric Mull · Guilford, US

Key dates

• Filing date: Apr 14, 2011
• Grant date: Jun 3, 2014
• Expiry date: Jan 10, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.